Table 1 Patient demographics.

From: Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer

Variable

Patients (n = 200)

Stage

 I

18 (9%)

 II

6 (3%)

 III

78 (39%)

 IV

98 (49%)

Histology

 High-grade serous

152 (76%)

 Mucinous

16 (8%)

 Clear cell

11 (5.5%)

 Endometrioid

11 (5.5%)

 Low-grade serous

2 (1%)

 Other

8 (4%)

 Initial PFI (median, IQR)

14.2 months (9.4–24.9 months)

Distribution based on PFI

 PFI < 6 months

18 (9%)

 PFI 6–12 months

59 (29.5%)

 PFI > 12 months

123 (61.5%)

BRCA status

 Wild type

157 (78.5%)

 Mutant

43 (21.5%)

  1. PFI platinum-free survival, IQR interquartile range.
Back to article page